Objectives: Certain patients ultimately undergo explantation of their spinal cord stimulation (SCS) devices. Understanding the predictors and rates of SCS explantation has important implications for healthcare resource utilization (HCRU) and pain management. The present study identifies explant predictors and discerns differences in HCRU for at-risk populations.
INTRODUCTION
Spinal cord stimulation (SCS) has been proven to be a safe and sustained therapy for refractory chronic pain (1) (2) (3) (4) , and has been shown to have a real effect in reducing healthcare expenditures over time (5) . Interest in SCS and its increased implementation in practice for multiple pain disciplines have grown in response to the increasing need for nonpharmacologic, multimodal approaches for long-term pain management (6) . Studies in 2006-2007 reported more than 20 ,000 spinal cord stimulators implanted annually (7) (8) (9) , a number that can be presumed to have grown with increasing patient and clinician awareness. Since its first introduction in the 1970s, and subsequent FDA approval in 1989 for treatment of trunk and extremity pain, there have been numerous studies in the literature demonstrating SCS efficacy to exceed that of conventional medical management alone in the treatment of a myriad of chronic pain symptoms (1, 10, 11) . SCS technology has made significant advancements in the past 10-15 years, such as novel stimulation settings (burst, high-frequency, continuous, position-adaptive) to better tailor coverage (12) . Recent studies have reported 70% of patients achieving >50% pain relief, greatly improved from the 40% reported in the 1970s (12) .
The ability to predict patient-by-patient success of SCS involves a variety of factors, including the success of trial implant, judicious patient selection, and postprocedure programming (13) (14) (15) (16) (17) (18) (19) (20) (21) . Nevertheless, lead migration and device failure are possible complications that can produce patient dissatisfaction (22) (23) (24) (25) . When SCS fails or becomes refractory over time, patients and providers must decide whether to leave the device in place or to remove the device through an explantation procedure. Though a relatively simple procedure, this necessitates return to the OR, with its associated risks and increased costs to the healthcare system. Newer interventions include novel stimulation paradigms that may provide renewed pain relief in such patients. Beyond considering patient and practitioner preference, there is limited data supporting one choice over the other with respect to improved patient outcome and healthcare expenditures.
We designed a retrospective analysis of the Truven MarketscanV R Database to explore the impact of explantation on healthcare resource utilization (HCRU) and to better understand the predictive factors leading to SCS explantation. Patients were analyzed pre-SCS, one-year post-SCS, and three-years post-SCS implant, with and without subsequent explant. We hypothesized that explantation occurs more frequently in medically complex patients, and results in higher HCRU costs at both one-year and three-year follow-up.
METHODS

Data Source
We utilized the Truven MarketScanV R Database, containing information on more than 200 million unique patients in the United States. This database culls from Commercial Claims and Encounters, Medicare Supplemental and Coordination of Benefits, and Medicaid, producing an aggregate of fully integrated patient-level data, including inpatient, outpatient, drug, and lab information. We performed a retrospective review of SCS patients from the years 2007-2012.
Patient Population
International Classification of Diseases, Ninth Revision, [ICD-9] diagnosis and Current Procedural Terminology (CPT-4) procedure codes were used to identify patients with permanent SCS implantation with or without subsequent explant. For inclusion in the study, patients had the diagnosis of chronic pain (including ICD-9 codes for postlaminectomy syndrome, CRPS, neuritis/radiculitis, limb pain, degenerative spine disease, back pain, and chronic pain) and underwent permanent SCS implantation with percutaneous or paddle leads (CPT-4: 63650, 63655) followed by placement of internal pulse generator (IPG) (CPT-4: 63685), with the date of IPG implant serving as permanent implantation date and the date of first SCS implant serving as the index event. Patients were separated into two cohorts: 1) those that received SCS lead explant (CPT-4: 63661, 63662) with or without concomitant IPG explant (CPT-4: 63688) at any time following initial permanent implant, and 2) explant-free patients in implant-to-index event time. Patients were expected to not have any subsequent follow-up related to neuromodulation (e.g., SCS analysis/programming CPT-4: 95970-95973) following explant. Additional inclusion criteria were: 18 years of age, 1-year follow-up time prior to permanent implantation, and 1-year follow-up time after index event. For the purposes of multivariate regression analysis, patient cohort was further divided into high (>25), medium (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) , and low (3) (4) (5) (6) (7) (8) 
Data Collection
Data were collected on patient age, gender, comorbidities, employment status, insurance type, region, and year of index event; longitudinal analysis was used to identify comparable patients for each cohort. HCRU categories included pain encounters, pharmaceutical expenditures, inpatient admissions, pain procedures, and total costs pre-and post-SCS follow up. All-cause and pain-related expenditures and visits, as well as cumulative HCRU at one-year after the index event, were calculated. Additional procedures performed within three-years after the index event (e.g., back surgery, intrathecal pain pumps, other nonsurgical medical management) were also counted.
Statistical Analysis
Descriptive statistics were reported and demarcated by explant vs. non-explant status. Counts and percentages were reported for categorical variables. Means, standard deviations, medians, and quartiles were provided for continuous variables. Chi-square test was used for the group difference for categorical variables, and Kruskal Wallis test was used for group difference for continuous variables. Negative and extremely large values were removed by excluding the highest and lowest 1% of pay. A longitudinal model was used to project healthcare system savings with % reduction in explant rate. This analysis used a GEE linear model with log transformed cost for patients with up to three-years of data after SCS lead implant. Each model included sex, age, employment status, year of SCS, insurance type, Charlson score, month of explant, explant status, follow-up months, and an interaction of follow-up month and explant. This analysis used a compound symmetry correlation structure for patients with multiple months of data (up to three-years). For count outcomes, Poisson regression was used. Cohort comparison for percentage utilization of additional types of procedures was performed using Chi-square or Fisher's exact tests. Kaplan-Meier curves and Cox proportional-hazards regression was used to compare occurrence of explant events. Adjusted Hazard ratios (HRs) with 95% confidence intervals (CIs) were reported for explant rates. All analyses were conducted with SAS version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Patient Cohort and Demographics
We identified 8727 unique patients that underwent SCS trials performed between 2007 and 2012. Overall, the patient cohort was 63.8% female with an average age of 52.1 6 13.3 years and an average Charlson comorbidity score of 0.9 at implantation, as calculated from records one-year prior to index event. The southern region comprised the largest geographic distribution (43.8%) of the patient cohort. 59.6% of patients were commercially insured and 24.3% were actively employed full-time. Descriptive statistics are provided in Table 1 .
Healthcare Resource Utilization
Baseline healthcare-related expenditures were obtained for patients one-year prior to the index event ( (Table 3) . At the month of explant, explant patients were expected to have incurred 2.65 times the total cost compared to the non-explant cohort (CR 2.65, 95% CI [1.83, 3 .84]; p < 0.001). Though statistically insignificant, in the month following explant, patients incurred a total cost that was 1.19 times that of non-explant patients (CR 1.19, 95% CI [0.82, 1.71]; p 5 0.363). Holding other covariates at fixed value, each unit increase of baseline Charlson score was associated with a 51% increase of total cost (CR 1.51, 95% CI [1.43, 1.59]; p < 0.001). For each month following SCS lead implant, non-explant patients were expected to experience a 6% decrease in total costs; this rate of cost savings decreases after undergoing explant (0.94*1.02 5 0.96, which is 4% decrease in costs). Similar trends are reflected for pain prescription and total medication costs in the explanted cohort. Furthermore, by the month of explant, patients in the explant cohort had 3.62 times more inpatient admissions than non-explant patients (RR 3.62, 95% CI [1.42, 9.26]; p 5 0.007). In the month following explant, patients had inpatient admissions that were 4.33 times that of non-explanted patients (RR 4.33, 95% CI [2.28, 8.21] ; p < 0.001). Again, each unit increase of baseline Charlson score resulted in a 23% increase in total inpatient admissions, when holding all other covariates fixed.
Predictors of Explantation
Multivariate regression analysis was performed to identify independent predictors of explantation at one-and three-years after initial SCS lead implantation (Table 4) Gender, insurance source, and employment status were not found to be independent predictors of explantation during the same periods.
Post-Explant Procedures
Overall, the explant cohort demonstrated increased use of procedures (median 19.0 vs. 9.0; p < 0.0001) compared to non-explanted patients (Table 5) . Injection use was significantly higher in the explanted group with an average of 1.7 injections (vs. 0.9 injections in non-explanted; p < 0.0001). About 3.8% of patients who were explanted subsequently underwent a repeat spinal cord stimulator trial (vs. 2.8% in non-explant; p < 0.0001).
DISCUSSION
Cost-effectiveness remains an ever-growing focus of healthcare practice, within which the treatment of chronic pain is a sizable target. In 2014, personal health care expenditures saw a 5% increase from 2013, totaling $2.6 trillion, with prescription drug expenditures totaling nearly $300 billion (26) . Chronic pain patients, in particular, represent a challenging cohort that requires long term, multimodal treatment. SCS has been shown to be an effective and costconscious treatment option, despite initial high costs associated with implantation (10) . Especially in the context of lumbar back pain, the most common cause of work-related disability in the otherwise healthy under-45 patient population (11) , SCS has the additional unmeasured benefit of regained productivity. However, the variability of training and in practice across providers result in unstandardized methods in SCS utilization. Research is especially limited in cases where SCS devices prove ineffective following permanent implantation. The provider and patient must then face the decision to explant the device, keep the device in place, or revise the device. The best practice and most economically efficient choice has yet to be determined. In this study, we evaluated how healthcare utilization differs in patients who ultimately undergo explantation up to three-years after an SCS trial and those who do not. SCS explant serves as a proxy for unsuccessful implant, whether from incomplete pain control or device malfunction. Thus, by delineating explant vs. nonexplant groups, we provide important insights into the cost of failed SCS treatment. Our analysis corroborated our hypothesis: the explant cohort was found to incur 2.65 times greater total cost compared to non-explant patients by the time they underwent explant. These patients also had a decrease in total costs that was lower than the controls (4 vs. 6%), as well as for pain prescriptions and total medications cost. Patients in the explant cohort also underwent significantly more procedures at three-years after initial SCS implant (sum 24.7 vs. 15.7), which most notably included injections and sympathetic blocks. The impact of SCS explantation on healthcare costs and utilization is striking; if explanted patients experience lower SCS efficacy, it follows that they undergo significantly more alternative treatment methods as adjuncts.
Although the HCRU results followed logically with our assumptions about unsuccessful treatment of painful symptomatology as requisite for explant, we found that medium-volume providers were associated with the lowest explant rates at one-year and three-years post-SCS, compared to their low-volume colleagues, but also compared to the high-volume providers. One interpretation of these results is that medium-volume implanters simply experience more success with SCS implant, likely due to a combination of a lower-risk patient population compared to high-volume providers from existing referral patterns, and increased experience compared to lowvolume providers. This does corroborate unpublished data from our group that demonstrated that medium-volume groups had overall superior HCRU in total, pain encounter, and pain prescription costs. It can be conjectured that high-volume providers are more often found in high-volume academic centers that tend to see sicker patients. As might be expected, each unit increase in Charlson comorbidity score was associated with an increase in total costs (51%). Thus, we infer that what we have chosen to define as SCS success in this study (i.e., low explant rate, lower HCRU) seen with medium-volume providers represents a "happy medium" calibration beginning with a better baseline patient population that leads to improved postoperative outcome, decreased complications or need for subsequent troubleshooting, and ultimately lower explant rates and costs incurred. Patient selection remains a critical aspect of SCS success and serves as an aspect of care that improves with experience (18, 19) . Additionally, providers with higher volume practices may have improved ancillary support staff and regular access to programming support services. It follows that the threshold for explantation increases if a provider has the capacity for continued calibration of device programming, a critical and oftentimes iterative step following device implantation. Further, although our data is complicated by coding differences before and after 2009 with regard to distinguishing between revision and explant, it is possible that mediumand high-volume providers tend to execute device revision(s) with higher thresholds for explant. Regardless, these results suggest that there are very real effects on outcomes as a result of different training requirements. Delineating the differences will be useful to further guide and calibrate successful training regimens to optimize provider proficiency and outcomes.
Although Marketscan is able to identify unique patient cohorts (explant vs. non-explant), there is no data that allows identification of why these explants occurred. Baseline demographics are available, but time to SCS, pre-surgical pain quality, symptomatology, QOL, and work-related productivity-factors related to the efficacy of SCS implant-are not. In a systematic review of 25 studies, Celestin et al. found that psychological factors including somatization, depression, anxiety, older age, and poor coping were useful in helping to predict poor outcomes to SCS (27) . Longer delay prior to SCS implant was also found to relate inversely to SCS success (28). Kumar et al. have reported an inverse correlation between long-term pain relief and implantation delay, with a critical time window of twoyears between pain syndrome onset and implantation. Within those two-years, >50% pain relief can be attained in 85% of patients, which decreases to 9% if the implantation delay is >15-years; this averaged to effective pain control in 60% of patients (29) . If the average wait time for SCS implantation is roughly five-years, as reported from their single-institution study, this certainly decreases long-term success rates. Interestingly, they also noted that non-implanting neurosurgeons referred to an implant physician around 1.7 times earlier than orthopedic surgeons and anesthesiologists (30), highlighting provider practice variability. Our results do not delineate provider types (orthopedic surgery, neurosurgery, pain management, and PM&R) within volume groups or procedure setting (acute care centers, private hospitals, or large academic centers); however, differences undoubtedly exist across different providers based on training, standard practice, and institutional variability.
It is assumed here that SCS explant is the corollary to unsuccessful pain control or device malfunction. Hayek et al. reported a 34.6% complication rate for percutaneous SCS implants in a cohort of 234 patients with noncancer pain, 74.1% of which were hardware related, and which led to a 23.9% rate of revision and explant each (24) . Explant was most commonly performed due to loss of therapeutic effect (24) . Other studies have reported complication rates of 43% with SCS (31), or 38% that were associated with hardware failures (e.g., lead migration, connection failure, breakage) (25) . These are fairly high complication levels reported from data generated at academic institutions, and prior to the advent of more recent technologic advances in stimulator engineering and settings. Per general practice, SCS failure is loosely defined as unsuccessful pain control after 12-16-weeks of multimodal medical management with other pain treatment adjuncts. IPG explant does not always imply lead explant. In our practice, nonfunctioning IPGs and leads are both extracted at time of explantation. Barring extremely difficult extraction, there is little reason to only explant the lead or the IPG-retention of a foreign body is associated with its own set of complications, especially as a nidus for infection. However, the decision to explant is one jointly made by patient and provider, and we recognize that not all nonfunctioning SCS systems are explanted. It is possible that patients who failed SCS opted instead to discontinue its use rather than undergo a procedure for removal, which we were unable to capture here. Although we could not differentiate this possibility, it is important to consider the patient and provider populations who decide to undergo explant, from those who "could" or "should" and choose not to undergo explant. There are several limitations to this study. First, this is a retrospective cohort analysis that uses unique instances of patients from a large, nationwide database. To address this, we performed multivariate analysis with regression covariates, and adjustment of appropriate patient and cost-related factors. Second, baseline clinical characteristics and other patient-related factors including pain intensity and quality of life could not be analyzed. Factors related to improved work-related productivity based on achieving pain relief through permanent implant were not accounted for in the cost analysis. Third, the database may not take into account the types of procedures or pain encounters that may contribute to varied healthcare resource utilization costs across the different providers. Lastly, the database does not account specifically for physician experience, patient selection, or customized spinal stimulator characteristics. This includes procedure details such as number of leads, lead placement, and dermatomal distribution of pain targets, all of which impact SCS success.
It should be noted that the explant group demonstrated higher costs prior to SCS implantation, an interesting association that we were unable to explore explicitly in this study. This potentially suggests that these eventual explant patients were from the outset less appropriate candidates for SCS. Perhaps they had undergone implantation as a "desperation" measure after failing multiple therapeutic measures, and this in turn could be due to multiple intrinsic patient and pathology characteristics, such as higher levels of somatization. Despite the aforementioned limitations, this study provides us with useful insights into understanding costs associated with SCS explantation rates. This is the first large-scale study to take an essential step towards identification of a patient cohort in an SCS community that undergoes SCS explantation. Follow-up studies are necessary to delineate underlying factors resulting in explantation, as well as the effect of provider and volume-based differences on explant rates.
CONCLUSION
This longitudinal, retrospective analysis found that SCS explantation is associated with total increased healthcare resource utilization and quantified its impact. There is a high financial cost burden associated with failed SCS systems. The SCS explant cohort had significantly higher baseline costs (median $42,140.3 vs. $27,821.7 in non-explant groups; p < 0.0001). At the month of explant, explant patients were expected to have incurred 2.65 times the total cost compared to the non-explant cohort (CR 2.65, 95% CI [1.83, 3 .84]; p < 0.001). Age of patient, medium provider volume, and Charlson index were found to be independent predictors of explantation. Medium-and high-volume SCS providers appear to experience fewer explantations. This has implications for clinician training, standardization of practice, and construction of meaningful national guidelines. Furthermore, the early identification of patient characteristics that may pose risk of increased explantation warrants further investigation of alternative treatment options for pain management.
including the number of cases performed, as well as the establishment of ancillary services needed to do a better job at the screening, maintenance and follow up process, among others, (1) . It is up to us to come to an agreement on how to develop this concept, and not wait until Medicare or another government agency decides to do it for us. The article does have some flaws, for example, data seems to be heavily based on the Southern region, which may not represent the practice of other parts of the US. Additionally, due to the retrospective nature of the study, it is impossible to determine the exact cause of the revision/explant. Nor can we determine how many of the patients that kept their stimulator are still benefiting from the therapy, whether their function has improved, or have reduced the number of medications they were using prior to the procedure.
A prospective study will be an excellent follow up to this work, so that we can become more certain of the findings. It was surprising to see that insurance was not a factor on predicting poor outcome. We always try to avoid workers comp cases on prospective studies because the risk of increasing the likelihood of a negative trial, however, in this work, disability patients were as likely to experience a good outcome as private payer patients. This clearly needs to be further studied.
Regardless of these controversies, again, this is an excellent study, worthy of consideration.
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